The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to
chronic release of a brain chemical called glutamate. Glutamate helps transmit messages
between nerve cells through interaction with a certain type of receptor
(N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of
excessive glutamate at the receptor (NMDA receptor antagonist).